{"entity":{"id":"nct00100243","kind":"trial","name":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","aka":[],"tldr":"A phase 2 trial of Abarelix in Prostate cancer, run by PRAECIS Pharmaceuticals Inc., completed.","summary":"Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy is a phase 2 interventional study registered as NCT00100243 by PRAECIS Pharmaceuticals Inc., with 22 participants recorded, started 2004-05. Interventions recorded: Plenaxis. Conditions recorded: Prostate Cancer.\n\nLinked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT00100243","url":"https://clinicaltrials.gov/study/NCT00100243"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abarelix"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT00100243","phase":"2","setting":"Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy","sponsor":"PRAECIS Pharmaceuticals Inc.","enrolled":22,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00100243/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"abarelix","kind":"drug","name":"Abarelix","route":"/drugs/abarelix/"}]}}